- Home
- KIM vs RDY Comparison
KIM vs RDY Comparison
Compare KIM & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- RDY
- Stock Information
- Founded
- KIM 1958
- RDY 1984
- Country
- KIM United States
- RDY India
- Employees
- KIM N/A
- RDY N/A
- Industry
- KIM Real Estate Investment Trusts
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- KIM Real Estate
- RDY Health Care
- Exchange
- KIM Nasdaq
- RDY Nasdaq
- Market Cap
- KIM 14.1B
- RDY 11.6B
- IPO Year
- KIM 1991
- RDY N/A
- Fundamental
- Price
- KIM $20.70
- RDY $14.00
- Analyst Decision
- KIM Buy
- RDY Strong Buy
- Analyst Count
- KIM 10
- RDY 1
- Target Price
- KIM $24.20
- RDY $16.90
- AVG Volume (30 Days)
- KIM 5.4M
- RDY 998.5K
- Earning Date
- KIM 10-30-2025
- RDY 10-24-2025
- Dividend Yield
- KIM 5.03%
- RDY 0.51%
- EPS Growth
- KIM 57.13
- RDY 9.95
- EPS
- KIM 0.83
- RDY 0.79
- Revenue
- KIM $2,123,057,000.00
- RDY $3,851,623,984.00
- Revenue This Year
- KIM $4.86
- RDY $6.29
- Revenue Next Year
- KIM $3.18
- RDY $2.61
- P/E Ratio
- KIM $24.84
- RDY $17.76
- Revenue Growth
- KIM 8.14
- RDY 14.10
- 52 Week Low
- KIM $17.93
- RDY $12.26
- 52 Week High
- KIM $25.83
- RDY $16.17
- Technical
- Relative Strength Index (RSI)
- KIM 49.13
- RDY 52.85
- Support Level
- KIM $19.86
- RDY $13.64
- Resistance Level
- KIM $20.83
- RDY $14.10
- Average True Range (ATR)
- KIM 0.33
- RDY 0.19
- MACD
- KIM 0.08
- RDY 0.04
- Stochastic Oscillator
- KIM 84.97
- RDY 87.88
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.